Monoclonal Antibodies Market to Grow at 11.8% CAGR to be Worth $243Bn, Globally, by 2028 - Exclusive Report by The Insight Partners

According to the new market research report "Monoclonal Antibodies Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Source (Human, Humanized, Chimeric, and Murine), Production Method (In-Vitro and In-Vivo), Indication (Cancer, Autoimmune Diseases, Infectious Diseases, Inflammatory Diseases, Microbial Diseases, and Others), Application (Therapeutic Applications, Diagnostic Applications, and Research Applications), and End-User (Hospitals, Others, and Research Institutes)", published by The Insight Partners, the global monoclonal antibodies market is projected to reach $243.05 billion by 2028 from $111.01 billion in 2021; it is expected to grow at a CAGR of 11.8% from 2021 to 2028.

Get Exclusive Sample Pages of Monoclonal Antibodies Market Size - COVID-19 Impact and Global Analysis with Strategic Insights at

Report Coverage


Market Size Value in

US$ 111.01 Billion in 2021

Market Size Value by

US$ 243.05 Billion by 2028

Growth rate

CAGR of 11.8% from 2021 to 2028

Forecast Period


Base Year


No. of Pages


No. Tables


No. of Charts & Figures


Historical data available


Segments covered

Source, Production Method, Indication, Application, and End-User

Regional scope

North America; Europe; Asia Pacific; Latin America; MEA

Country scope

US, UK, Canada, Germany, France, Italy, Australia, Russia, China, Japan, South Korea, Saudi Arabia, Brazil, Argentina

Report coverage

Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Inquiry Before Buying:

Monoclonal Antibodies Market Analysis: Competitive Landscape and Key Developments

Novartis AG; Pfizer Inc.; GlasxoSmithKline plc.; Amgen Inc.; DAICHI SANKYO COMPANY LIMITED; F. HOFFMANN-LA ROCHE LTD.; AstraZeneca; Elli Lilly and Company; Bayer AG; Bristol-Myers Squibb Company are among the key companies operating in the monoclonal antibodies market. The market leaders focus on new product launches, expansion and diversification, and acquisition strategies, which allow them to tap into prevailing business opportunities.

In July 2021, Roche announced the approval "Ronapreve" (casirivimab and indevimab) for treating patients with mild to moderate COVID-19 via intravenous infusion. The antibody combination was granted a Special Approval under Article 14-3 of the Pharmaceuticals and Medical Devices Act.

In September 2021, Amgen, Inc. announced the first combination study results from the phase 1b/2 CodeBreak 101 study intended for the patients with KRAS G12C mutated advanced colorectal cancer. The results state that the combination of drugs enhances the efficiency and safety of the treatment.       

Speak to Research Analyst:

According to the World Health Organization (WHO) report, cancer is a leading cause of death globally, and it accounted for ~10 million deaths in 2020. Additionally, 30–50% of cancer cases can be prevented by avoiding exposure to risks factors and implementing existing evidence-based prevention strategies. A correct cancer diagnosis is essential for appropriate and effective treatment. A report by the National Institute of Health (NIH) states that monoclonal antibodies can be used for treating cancer. These antibodies serve as a type of targeted cancer therapy. Many monoclonal antibody products have been approved for treating a wide variety of cancers. For example, "Rituximab" a chimeric mouse/human monoclonal antibody was the first therapeutic antibody approved and intended for use in oncology purposes; it was recognized as a top-selling oncology drug for nearly a decade, as its sales reached US$ 8.58 billion in 2016. These factors are fueling the growth of the overall monoclonal antibodies market.

The increased demand for monoclonal antibodies (mABs) amid the COVID-19 pandemic has been stimulating the growth of the monoclonal antibodies market. In response to high transmission and severe mortality rates, the Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for three monoclonal antibodies intended for outpatient treatment of symptomatic COVID-19 patients. Monoclonal antibody treatments with "bamlanivimab", "casirivimab/imdevimab", and "bamlanivimab/etesevimab" were approved in November 2020 and April 2021 by the Centers of Medicare and Medicaid Services. According to a report by the NCBI, 2.5 million monoclonal antibody treatments were purchased by the US Government, and ~1 million treatments were allocated to states. Furthermore, the South Carolina Department of Health and Environmental Control report states that an mAB treatment for people suffering from COVID-19 has been approved by the FDA only for emergency use, as it was found successful in reducing hospitalization and death by almost 70%, and shortening treatments window by an average of 4 days. For records, South Carolina Department of Health and Environmental Control report in October 2021, states that, 32,686 COVID-19 patients in South Carolina have been treated with monoclonal antibodies with no adverse reactions.

Buy Premium Copy of Monoclonal Antibodies Market Size, Share, Revenue, Strategic Insights and Forecasts 2021-2028 Research Report at

Browse Adjoining Reports:

Cancer Monoclonal Antibodies Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type (Murine Antibodies, Chimeric Antibodies, and Humanized Antibodies); Therapies (Bevacizumab, Rituximab, Trastuzumab, Cetuximab, Panitumumab, and Other Monoclonal Antibody Therapies); Application (Breast Cancer, Blood Cancer, Liver Cancer, Brain Cancer, Colorectal Cancer, Lung Cancer, and Others), and Geography

CD38 Monoclonal Antibodies Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type (Daratumumab, Isatuximab); Application (Pharmacy, Laboratory Use) and Geography

Peripheral T-Cell Lymphoma Treatment Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Therapy (Chemotherapy, Radiation Therapy, Monoclonal Antibodies Therapy, Others); End User (Hospitals, Clinics, Ambulatory Surgical Centers, Others)

Pancreatic Beta-Cell Protection Market Forecast to 2028 - COVID-19 Impact and Global Analysis by Product (Stem Cell Based, Gene Therapies, RNA Based Therapies, Monoclonal Antibodies (MAbs), Phytotherapy); Applications (Hospital, Medical Research Laboratory, Others)

HER2 Antibodies Market Forecast to 2028 - Covid-19 Impact and Global Analysis - By Type (Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab, Everolimus)

Research Antibodies Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product (Antibodies and Reagents), Technology (Western Blotting, Flow Cytometry, Enzyme-linked Immunosorbent Assay, Immunoprecipitation, Immunohistochemistry, Immunofluorescence, and Other Technologies), Application (Proteomics, Drug Development and Genomics); End User (Academic & Research Institutes, Pharmaceutical & Biotechnological Companies and Contract Research Organizations) and Geography

Secondary Antibodies Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type (Human Antibodies, Animal Antibodies); Applications (ELISA, Western blot, Immunostaining, Immunohistochemistry, Immunocytochemistry),Impact of covid-19 pandemic.

Antibodies Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type (Monoclonal Antibodies, Polyclonal Antibodies, ADCs, Others); Technology (Western Blotting, Flow Cytometry, ELISA, Immunohistochemistry, Immunofluorescence, Immunoprecipitation, Others); Application (Proteomics, Drug Development, Genomics); End-User (Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, CRO's), and Geography

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

Contact Us:

If you have any queries about this report or if you would like further information, please contact us:

Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Press Release:



Back to news